Novogen Limited (NASDAQ:KZIA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Novogen Limited (NASDAQ:KZIA) have earned an average rating of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $26.3333.

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th. BTIG Research reiterated a “buy” rating and set a $34.00 price objective on shares of Novogen in a research note on Wednesday, July 15th. Canaccord Genuity Group started coverage on Novogen in a report on Thursday, August 13th. They set a “buy” rating and a $29.00 target price on the stock. Finally, Lake Street Capital started coverage on Novogen in a research report on Thursday, June 11th. They issued a “buy” rating and a $32.00 target price for the company.

Novogen Trading Down 1.5%

Shares of KZIA opened at $13.20 on Tuesday. The firm has a 50-day moving average price of $13.41 and a 200 day moving average price of $11.00. Novogen has a 52-week low of $4.86 and a 52-week high of $17.40.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.